Tags

Type your tag names separated by a space and hit enter

Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb.
Toxins (Basel). 2014 Aug 19; 6(8):2471-82.T

Abstract

Medically important cases of snakebite in Europe are predominately caused by European vipers of the genus Vipera. The mainstay of snakebite therapy is polyclonal antibody therapy, referred to as antivenom. Here we investigate the capability of the monospecific V. berus antivenom, ViperaTAb®, to cross-react with, and neutralise lethality induced by, a variety of European vipers. Using ELISA and immunoblotting, we find that ViperaTAb® antibodies recognise and bind to the majority of toxic components found in the venoms of the Vipera species tested at comparably high levels to those observed with V. berus. Using in vivo pre-clinical efficacy studies, we demonstrate that ViperaTAb® effectively neutralises lethality induced by V. berus, V. aspis, V. ammodytes and V. latastei venoms and at much higher levels than those outlined by regulatory pharmacopoeial guidelines. Notably, venom neutralisation was found to be superior to (V. berus, V. aspis and V. latastei), or as equally effective as (V. ammodytes), the monospecific V. ammodytes "Zagreb antivenom", which has long been successfully used for treating European snake envenomings. This study suggests that ViperaTAb® may be a valuable therapeutic product for treating snakebite by a variety of European vipers found throughout the continent.

Authors+Show Affiliations

MicroPharm Limited, Station Road Industrial Estate, Newcastle Emlyn, Carmarthenshire SA38 9BY, UK. n.r.casewell@liv.ac.uk.MicroPharm Limited, Station Road Industrial Estate, Newcastle Emlyn, Carmarthenshire SA38 9BY, UK. i.abdulla@micropharm.co.uk.MicroPharm Limited, Station Road Industrial Estate, Newcastle Emlyn, Carmarthenshire SA38 9BY, UK. david.smith@micropharm.co.uk.MicroPharm Limited, Station Road Industrial Estate, Newcastle Emlyn, Carmarthenshire SA38 9BY, UK. recoxon@micropharm.co.uk.MicroPharm Limited, Station Road Industrial Estate, Newcastle Emlyn, Carmarthenshire SA38 9BY, UK. enquiries@micropharm.co.uk.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

25153254

Citation

Casewell, Nicholas R., et al. "Immunological Cross-reactivity and Neutralisation of European Viper Venoms With the Monospecific Vipera Berus Antivenom ViperaTAb." Toxins, vol. 6, no. 8, 2014, pp. 2471-82.
Casewell NR, Al-Abdulla I, Smith D, et al. Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb. Toxins (Basel). 2014;6(8):2471-82.
Casewell, N. R., Al-Abdulla, I., Smith, D., Coxon, R., & Landon, J. (2014). Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb. Toxins, 6(8), 2471-82. https://doi.org/10.3390/toxins6082471
Casewell NR, et al. Immunological Cross-reactivity and Neutralisation of European Viper Venoms With the Monospecific Vipera Berus Antivenom ViperaTAb. Toxins (Basel). 2014 Aug 19;6(8):2471-82. PubMed PMID: 25153254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunological cross-reactivity and neutralisation of European viper venoms with the monospecific Vipera berus antivenom ViperaTAb. AU - Casewell,Nicholas R, AU - Al-Abdulla,Ibrahim, AU - Smith,David, AU - Coxon,Ruth, AU - Landon,John, Y1 - 2014/08/19/ PY - 2014/06/12/received PY - 2014/08/13/revised PY - 2014/08/13/accepted PY - 2014/8/26/entrez PY - 2014/8/26/pubmed PY - 2015/4/1/medline SP - 2471 EP - 82 JF - Toxins JO - Toxins (Basel) VL - 6 IS - 8 N2 - Medically important cases of snakebite in Europe are predominately caused by European vipers of the genus Vipera. The mainstay of snakebite therapy is polyclonal antibody therapy, referred to as antivenom. Here we investigate the capability of the monospecific V. berus antivenom, ViperaTAb®, to cross-react with, and neutralise lethality induced by, a variety of European vipers. Using ELISA and immunoblotting, we find that ViperaTAb® antibodies recognise and bind to the majority of toxic components found in the venoms of the Vipera species tested at comparably high levels to those observed with V. berus. Using in vivo pre-clinical efficacy studies, we demonstrate that ViperaTAb® effectively neutralises lethality induced by V. berus, V. aspis, V. ammodytes and V. latastei venoms and at much higher levels than those outlined by regulatory pharmacopoeial guidelines. Notably, venom neutralisation was found to be superior to (V. berus, V. aspis and V. latastei), or as equally effective as (V. ammodytes), the monospecific V. ammodytes "Zagreb antivenom", which has long been successfully used for treating European snake envenomings. This study suggests that ViperaTAb® may be a valuable therapeutic product for treating snakebite by a variety of European vipers found throughout the continent. SN - 2072-6651 UR - https://www.unboundmedicine.com/medline/citation/25153254/Immunological_cross_reactivity_and_neutralisation_of_European_viper_venoms_with_the_monospecific_Vipera_berus_antivenom_ViperaTAb_ L2 - https://www.mdpi.com/resolver?pii=toxins6082471 DB - PRIME DP - Unbound Medicine ER -